Drug

Didanosine

Established medicine

ClassHuman immunodeficiency virus type 1 reverse transcriptase inhibitorResearchOngoing clinical research

Also known as 2',3'-dideoxyinosine, 9-((2R,5S)-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-1H-purin-6(9H)-one, 9-((2S,5R)-5-Hydroxymethyl-tetrahydro-furan-2-yl)-9H-purin-6-ol, Dideoxyinosine+8 more

2',3'-dideoxyinosine, 9-((2R,5S)-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-1H-purin-6(9H)-one, 9-((2S,5R)-5-Hydroxymethyl-tetrahydro-furan-2-yl)-9H-purin-6-ol, Dideoxyinosine, Videx, Videx EC, ddI, ddIno, Didanosina, 2,3-Dideoxyinosine, 9-((2R,5S)-5-Hydroxymethyl-tetrahydro-furan-2-yl)-1,9-dihydro-purin-6-one, Didanosinum.

RxNorm3364 ChEMBLCHEMBL1460 ATCJ05AF02UNIIK3GDH6OH08

Reverse transcriptase/RNaseH

Primary target

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

A Randomized Trial to Evaluate the Effectiveness of Antiretroviral Therapy Plus HIV Primary Care Versus HIV Primary Care Alone to Prevent the Sexual Transmission of HIV-1 in Serodiscordant Couples

Clinical trial2021-11-05Results posted · ClinicalTrials.gov

An Open-Label Study to Evaluate the Safety, Tolerance, Antiviral Activity, and Pharmacokinetics of Emtricitabine in Combination With Efavirenz and Didanosine in a Once-Daily Regimen in HIV Infected, Antiretroviral Therapy Naive or Very Limited Antiretroviral Exposed Pediatric Subjects

Clinical trial2021-11-05Results posted · ClinicalTrials.gov

A Phase III, Randomized, Open-Label Trial to Evaluate Strategies for Providing Antiretroviral Therapy to Infants Shortly After Primary Infection in a Resource Poor Setting

Clinical trial2021-11-02Results posted · ClinicalTrials.gov

A Phase II, Double-Blind, Randomized Study to Determine the Effect of Adding Delayed Versus Immediate Hydroxyurea to a Genotypic Based, ddI-Containing, Three-Drug Antiretroviral Regimen on the Recovery of Total CD4+ T-Cell Counts and Suppression of Plasma Viral Load in Advanced HIV-1 Infected Subjects Failing a First or Second Triple Combination Therapy

Clinical trial2021-11-01Withdrawn · ClinicalTrials.gov

A Prospective Randomized Open-Label Clinical Trial to Evaluate the Comparative Efficacy and Safety of a Potent Antiretroviral Treatment Regimen With or Without Hydroxyurea for Subjects With Acute HIV-1 Infection or Recent HIV-1 Seroconversion

Clinical trial2021-11-01Withdrawn · ClinicalTrials.gov

Multicenter, Pilot Study of Telbivudine (LdT) Anti-HBV Treatment Prior to the Initiation of Highly Active Antiretroviral Therapy Containing Lamivudine in Subjects Coinfected With HBV and HIV

Clinical trial2021-11-01Withdrawn · ClinicalTrials.gov

Randomized, Open-Label Evaluation of Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations for Initial Treatment of HIV-1 Infected Persons From Resource-Limited Settings (PEARLS) Trial

Clinical trial2018-10-10Results posted · ClinicalTrials.gov

PROSPECTIVE NON-RANDOMIZED STUDY WITH CHEMOTHERAPY FOR RELAPSED OR REFRACTORY HIV-RELATED NON-HODGKIN'S LYMPHOMA: VMP REGIMEN FOR RELAPSED PATIENTS, CDE REGIMEN FOR REFRACTORY PATIENTS

Clinical trial2013-09-20Status unknown · ClinicalTrials.gov

Randomized, Controlled, Open Label, Multi-Center Phase III Trial Comparing the Safety and Antiviral Activity of a Protease-Containing Regimen (d4T/ddI/IDV/RTV) Versus a Protease-Sparing Regimen (d4T/ddI/EFV) and the Ability of Interleukin-2 to Purge HIV From Latent Stores in Patients With Acute/Early HIV Infection

Clinical trial2013-09-06Completed · ClinicalTrials.gov

A Randomized, Controlled Trial of Two Potent, Simplified Regimens Utilizing A Protease Inhibitor-Sparing Regimen Versus A Nucleoside-Sparing Regimen for HIV-Infected Subjects Who Participated in ACTG 388 or Who Responded to A First Potent Combination Regimen and Have 200 or Less HIV-1 RNA Copies/ml

Clinical trial2013-07-29Completed · ClinicalTrials.gov

Randomized, Open-Label 2x2 Factorial Study to Compare the Safety and Efficacy of Different Combination Antiretroviral Therapy Regimens in Treatment Naive Patients With Advanced HIV Disease and/or CD4+ Cell Counts Less Than 200 Cells/MicroL

Clinical trial2013-05-21Results posted · ClinicalTrials.gov

A Phase II Efficacy Study Comparing 2',3'-Dideoxyinosine (ddI) (BMY-40900) and Zidovudine Therapy of Patients With HIV Infection Who Have Been on Long Term Zidovudine Treatment

Clinical trial2011-03-14Completed · ClinicalTrials.gov

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Didanosine

Aliases & brands

2',3'-dideoxyinosine9-((2R,5S)-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-1H-purin-6(9H)-one9-((2S,5R)-5-Hydroxymethyl-tetrahydro-furan-2-yl)-9H-purin-6-olDideoxyinosineVidexVidex ECddIddInoDidanosina2,3-Dideoxyinosine9-((2R,5S)-5-Hydroxymethyl-tetrahydro-furan-2-yl)-1,9-dihydro-purin-6-oneDidanosinum

RxNorm CUI

3364

ChEMBL ID

CHEMBL1460

ATC codes

J05AF02

UNII

K3GDH6OH08

Primary mechanism

Human immunodeficiency virus type 1 reverse transcriptase inhibitor

Pharmacology & targets

1 target

Known molecular targets and mechanisms supported by curated pharmacology databases.

Reverse transcriptase/RNaseH

pol · Q72547

INHIBITORHuman immunodeficiency virus type 1 reverse transcriptase inhibitor

Clinical trials

122 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme

CLINICALTRIALS.GOV · LIVE REGISTRY

122

registered trials across all phases

LATEST COMPLETION 2015

Late-stage (III+)

110

Completed

Discontinued

PHASE DISTRIBUTIONn = 122

Phase 127Phase 1 / 21Phase 246Phase 318Phase 47Phase N / A23

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

CompletedPH IVKey trialAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infectionsn=1,5712010

CompletedPH IVKey trialNational Institutes of Health Clinical Center (CC)n=1,7712008

Analysis of Lipodystrophy in HIV-Infected Individuals A Prospective, Non-randomised, 48 Week Study of the Effect of PI Containing and Non-PI Containing Antiretroviral Regimens on the Expression of Adipocyte Specific Genes, Protein Levels and Cellular Structure in HIV-infected Individuals, Naive to Therapy, Who Are Starting Therapy for the First Time

CompletedPH IVKirby Instituten=802007

A Multiclinic, Open Pilot Study to Investigate the Effect of Combination Antiretroviral Therapy Including Indinavir Sulfate on Coagulation Factors, on Platelet Aggregation, and on Factor VIII/IX Half-Life in HIV-1 Seropositive Patients With Hemophilia A or B

CompletedPH IVMerck Sharp & Dohme LLCn=552005

A Randomized, Open-Label, Study of Nelfinavir or Efavirenz in HIV-1 Infected, Antiretroviral Naive Patients

Unknown statusPH IVAgouron Pharmaceuticalsn=2002005

Recent completions

Trials that read out recently, adding to the completed evidence base.

A Randomized Trial to Evaluate the Effectiveness of Antiretroviral Therapy Plus HIV Primary Care Versus HIV Primary Care Alone to Prevent the Sexual Transmission of HIV-1 in Serodiscordant Couples

CompletedPH IIIKey trialNational Institute of Allergy and Infectious Diseases (NIAID)n=3,5262015

A Phase III, Randomized, Open-Label Trial to Evaluate Strategies for Providing Antiretroviral Therapy to Infants Shortly After Primary Infection in a Resource Poor Setting

CompletedPH IIINational Institute of Allergy and Infectious Diseases (NIAID)n=3772013

CompletedPH IVKey trialAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infectionsn=1,5712010

HAART Regimen Comprising 3TC + ddI + EFV in Once-daily Administration in HIV-1 Infected Children in Burkina Faso

CompletedPH IIFrench National Agency for Research on AIDS and Viral Hepatitisn=522009

A Phase 2, One Arm, Open Label, Feasibility Study Assessing One Month Zidovudine/Didanosine Postpartum Prophylaxis to Prevent Resistance Mutations in Mothers Exposed to Single Dose Nevirapine to Prevent Mother to Child Transmission of HIV

CompletedPH IIInstitut de Recherche pour le Developpementn=2442009

CompletedPH I/IINational Institute of Allergy and Infectious Diseases (NIAID)n=432009

References & data sources

RxNorm (U.S. National Library of Medicine) — drug identity
ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
ClinicalTrials.gov — clinical trials